INDIANAPOLIS (dpa-AFX) - Eli Lilly and Co. (LLY), Friday announced the
decision to increase investment in Lebanon, Indiana manufacturing facility from
$3.7 billion to $9 billion to enhance production of Zepbound and Mounjaro
injections used for the treatment of obesity and type-2 diabetes, respectively.

Through the investment, Lilly expects to create an additional 200 full-time jobs
and more than 5,000 construction jobs during the site's development.

Additionally, the company is planning to expand across new locations such as
Research Triangle Park and Concord, North Carolina; Limerick, Ireland; and
Alzey, Germany.

Currently, Lilly's stock is moving down 0.05 percent, to $808.02 on the New York
Stock Exchange.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX